MEPSEVII Trademark

Trademark Overview

On Tuesday, January 10, 2017, a trademark application was filed for MEPSEVII with the United States Patent and Trademark Office. The USPTO has given the MEPSEVII trademark a serial number of 87295206. The federal status of this trademark filing is REGISTERED as of Tuesday, February 19, 2019. This trademark is owned by Ultragenyx Pharmaceutical Inc.. The MEPSEVII trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in treating genetic disorders, autosomal disorders, lysosomal storage disorders and enzyme disorders
mepsevii

General Information

Serial Number87295206
Word MarkMEPSEVII
Filing DateTuesday, January 10, 2017
Status700 - REGISTERED
Status DateTuesday, February 19, 2019
Registration Number5681146
Registration DateTuesday, February 19, 2019
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 28, 2017

Trademark Statements

Goods and ServicesPharmaceuticals for use in treating genetic disorders, autosomal disorders, lysosomal storage disorders and enzyme disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 17, 2017
Primary Code005
First Use Anywhere DateWednesday, December 20, 2017
First Use In Commerce DateWednesday, December 20, 2017

Trademark Owner History

Party NameUltragenyx Pharmaceutical Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNovato, CA 94949
Party NameUltragenyx Pharmaceutical Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNovato, CA 94949
Party NameUltragenyx Pharmaceutical Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNovato, CA 94949

Trademark Events

Event DateEvent Description
Monday, February 19, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, February 19, 2019REGISTERED-PRINCIPAL REGISTER
Friday, January 18, 2019NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, January 17, 2019ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, January 17, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 17, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 14, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, September 17, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, September 17, 2018NON-FINAL ACTION E-MAILED
Monday, September 17, 2018SU - NON-FINAL ACTION - WRITTEN
Monday, September 17, 2018STATEMENT OF USE PROCESSING COMPLETE
Tuesday, August 21, 2018USE AMENDMENT FILED
Monday, September 17, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, August 21, 2018TEAS STATEMENT OF USE RECEIVED
Wednesday, July 25, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 23, 2018SOU EXTENSION 1 GRANTED
Monday, July 23, 2018SOU EXTENSION 1 FILED
Monday, July 23, 2018SOU TEAS EXTENSION RECEIVED
Tuesday, January 23, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 28, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 28, 2017PUBLISHED FOR OPPOSITION
Wednesday, November 8, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, October 26, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, October 20, 2017ASSIGNED TO LIE
Friday, October 6, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, October 5, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 4, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 4, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 4, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 4, 2017NON-FINAL ACTION E-MAILED
Tuesday, April 4, 2017NON-FINAL ACTION WRITTEN
Tuesday, April 4, 2017ASSIGNED TO EXAMINER
Tuesday, January 17, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 13, 2017NEW APPLICATION ENTERED

Related Keywords

mepsevii disorders storage enzyme lysosomal autosomal genetic pharmaceuticals treating